Posts

Posted on

SMTC Investors Have Opportunity to Lead Semtech Corporation Securities Fraud Lawsuit

PR Newswire


NEW YORK
, April 10, 2025 /PRNewswire/ — 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Semtech Corporation (NASDAQ: SMTC) between August 27, 2024 and February 7, 2025, both dates inclusive (the “Class Period”), of the important April 22, 2025 lead plaintiff deadline.

So what: If you purchased Semtech securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Semtech class action, go to https://rosenlegal.com/submit-form/?case_id=35642 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 22, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Semtech’s CopperEdge products did not meet the needs of its server rack customer or end users; (2) that, as a result, the CopperEdge products required certain rack architecture changes; (3) as a result of the foregoing, Semtech’s sales of CopperEdge products would not ramp-up during the 2026 fiscal year; (4) as a result, sales of CopperEdge products would be lower-than-expected; and (5) as a result of the foregoing, defendants’ positive statements about Semtech’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Semtech class action, go to https://rosenlegal.com/submit-form/?case_id=35642 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/smtc-investors-have-opportunity-to-lead-semtech-corporation-securities-fraud-lawsuit-302426020.html

SOURCE THE ROSEN LAW FIRM, P. A.

Posted on

Manitowoc Files Anti-dumping Duty Petition in the U.S.

Manitowoc Files Anti-dumping Duty Petition in the U.S.

MILWAUKEE–(BUSINESS WIRE)–
The Manitowoc Company, Inc. (NYSE: MTW), (the “Company” or “Manitowoc”) a leading global manufacturer of cranes and lifting solutions, filed an anti-dumping petition with the U.S. International Trade Commission and U.S. Department of Commerce alleging predatory dumping by producers of lattice-boom crawler cranes from Japan.

Aaron H. Ravenscroft, President and Chief Executive Officer of The Manitowoc Company, Inc., stated, “Our action today clearly indicates that Kobelco’s behaviors have harmed our U.S. lattice-boom crawler crane operations. We trust that the U.S. Government will swiftly take action to level the playing field in support of our hardworking U.S. employees.”

Please review the Company’s filing at the following link: ACCESS.

About The Manitowoc Company, Inc.

The Manitowoc Company was founded in 1902 and has over a 120-year tradition of providing high-quality, customer-focused products and support services to its markets. Manitowoc is one of the world’s leading providers of engineered lifting solutions. Manitowoc, through its wholly-owned subsidiaries, designs, manufactures, markets, and supports comprehensive product lines of mobile hydraulic cranes, lattice-boom crawler cranes, boom trucks, and tower cranes under the Aspen Equipment, Grove, Manitowoc, MGX Equipment Services, National Crane, Potain, and Shuttlelift brand names.

Ion Warner

SVP, Marketing and Investor Relations

+1 414-760-4805

[email protected]

KEYWORDS: United States North America Wisconsin

INDUSTRY KEYWORDS: Architecture Machinery Professional Services Other Construction & Property White House/Federal Government Commercial Building & Real Estate Other Manufacturing Construction & Property Engineering Legal Urban Planning Public Policy/Government Manufacturing

MEDIA:

Logo
Logo
Posted on

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

PR Newswire


CRANBURY, N.J.
, April 10, 2025 /PRNewswire/ — Palatin Technologies, Inc. (the “Company”) (NYSE American:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced today that on April 10, 2024, NYSE American LLC (“NYSE American”) publicly announced and provided a notice to the Company that NYSE Regulation has determined to commence proceedings to delist the Company’s common stock (the “Common Stock”) from NYSE American. NYSE Regulation has determined the Company is no longer suitable for listing pursuant to Section 1009(a) of the NYSE American Company Guide as the Company was unable to demonstrate that it had regained compliance with Sections 1003(a)(i), (ii) and (iii), related to stockholders’ equity requirements, by the end of the maximum 18-month compliance plan period, which expired on April 10, 2025.

The Company has a right to a review of the NYSE Regulation determination to delist the Common Stock by the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange (the “Panel”). The Company’s request for such a review must be made by April 25, 2025. The Company intends to appeal such determination to delist the Common Stock. The Company expects the Common Stock to continue to trade on NYSE American during the appeal process.

Following such appeal, a decision by the Panel will be made and announced by NYSE American regarding either proceeding with suspension and delisting or continued trading in the Common Stock. The Company is working diligently to regain compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide. However, there can be no assurance that the Company will regain compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide before any hearing occurs.


Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about the Company’s appeal of the delisting determination or the Company’s expectation that it may be able to regain compliance, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the Company’s actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements.

Palatin Technologies® is a registered trademark of Palatin Technologies, Inc.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-technologies-inc-announces-receipt-of-nyse-american-notice-of-delisting-and-intention-to-appeal-302426045.html

SOURCE Palatin Technologies, Inc.

Posted on

Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

Filing provisional patent application with the USPTO entitled “PSMA-Targeted PARP Inhibitor conjugates for Precision Cancer Therapy” key to advancement of Diagnostic and Therapeutic programs

Dr. Alan Kozikowski, internationally acclaimed pioneer in the discovery of a critical PSMA targeting ligand for clinical applications is co-inventor

Theranostic molecule designed to preferentially target prostate cancer cells to the effects of radiation and chemotherapeutic agents

GAITHERSBURG, Md., April 10, 2025 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the filing of a key provisional patent application with the United States Patent and Trademark Office (USPTO) entitled “PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy.”

The filing is yet another critical advancement within the Company’s Diagnostic subsidiary which aims to develop highly specific and effective theranostic agents for metastatic castration-resistant prostate cancer, leveraging its high expression on prostate cancer cells for accurate imaging and for targeted therapy delivery using radio labelled PSMA ligands.

The filing comes through Shuttle Pharma’s collaboration with internationally renowned medicinal chemist, Dr. Alan Kozikowski. Dr. Kozikowski’s original medicinal chemistry research performed in collaboration with Professor Joseph Neale and conducted at Georgetown University Medical Center were a component in the creation of both Pylarify and Pluvitco.

This is the second patent application covering intellectual property that was discovered as part of that project. The concept of targeting cellular antigens using antibody-drug-conjugates (ADCs) has been an active and promising area of research over the past decade. Since the PSMA targeting ligands are much smaller in size, and offer potential advantages for more efficient drug delivery, at least for prostate cancer treatment, this may offer a promising avenue of research.

Shuttle Diagnostics is a wholly owned subsidiary of Shuttle Pharma which aims to develop pretreatment diagnostic blood tests for prostate cancer patients. Current focus is on both, the PSMA-B ligand, as well as the PC-Rad test for predicting outcomes following radiation therapy for localized prostate cancer. There are currently no available tests on the market that are predictive of success for a specific treatment.

“I believe a significant opportunity exists for PSMA ligands for prostate cancer diagnosis and treatment,” commented Anatoly Dritschilo, MD, Shuttle Pharma’s Chairman and Chief Scientific Officer. “The Shuttle Pharma scientists have collaborated with Dr. Kozikowski on discovery projects for radiation sensitizing drugs and have recently focused on discovery of novel PSMA ligands with the intent of targeting prostate cancer cells preferentially to the effects of radiation and chemotherapeutic agents. We look forward to the continued advancement of our Shuttle Diagnostics’ subsidiary and the opportunity to develop a theranostic that has the potential to play a significant role in the future diagnosis and treatment of prostate cancer.”

According to the American Cancer Society, 1 in 8 men will be diagnosed with prostate cancer during their lifetimes. At initial diagnosis, approximately half of the patients present with early-stage prostate cancer for which curative management is available either through surgery or radiation therapy. Patients who present with metastatic prostate cancers that have spread beyond the prostate are managed with androgen deprivation therapy, cytotoxic chemotherapeutic agents or radiopharmaceuticals to inhibit cancer growth. However, toxicities resulting from off-target effects of cytotoxic agents limit the doses of drug that can be administered and result in poor patient acceptance of such treatments.

Most prostate cancers express the PSMA antigen on the surface of cancer cells. Discovery of a peptide PSMA ligand that binds to the PSMA molecule with high affinity has enabled development of targeted diagnostic and therapeutic agents and stimulated research and the pharmaceutical industry to build on the PSMA targeting concept. Indeed, incorporation of various radioisotopes into molecules containing the PSMA ligand have demonstrated applications for imaging prostate cancer (PET Scanning) and for treatment of metastatic prostate cancer using radiopharmaceuticals.

We believe a significant opportunity exists for PSMA ligands for prostate cancer diagnosis and treatment, particularly in the development of highly specific and effective theranostic agents for metastatic castration-resistant prostate cancer, leveraging its high expression on prostate cancer cells for accurate imaging and targeted therapy delivery using radio labelled PSMA ligands. According to Clarivate, the Global PSMA PET Imaging Market reached $1.5 billion in 2022 and is expected to reach $2.0 billion by 2030. Pluvitco®, a targeted radiopharmaceutical treatment for PSMA-positive metastatic prostate cancer, has a predicted market size of $2 billion.


About Shuttle Pharmaceuticals

Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.


Safe Harbor Statement

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of Shuttle Pharma’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 24, 2025, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Shuttle Pharmaceuticals

Anatoly Dritschilo, M.D.
Chairman and Chief Scientific Officer
240-403-4212
[email protected]

Investor Contacts

Lytham Partners, LLC
Robert Blum
602-889-9700
[email protected] 



Posted on

374Water Announces Settlement of Claim

DURHAM, N.C., April 10, 2025 (GLOBE NEWSWIRE) — 374Water Inc. (NASDAQ: SCWO) (“374Water” or the “Company”), a global leader in organic waste destruction technology for municipal, federal, and industrial markets, today announced that it has reached a settlement with its co-founder and former Chief Executive Officer, Yaacov (Kobe) Nagar, regarding an employment claim that had been filed against the Company. Both parties are pleased to resolve the matter amicably and look forward to future opportunities for collaboration.

The terms of the settlement are confidential, but both parties are satisfied with the resolution and believe that it will allow for a positive and productive relationship going forward.

“We are pleased to have reached a fair and mutually beneficial settlement with Mr. Nagar,” said Chris Gannon, Chief Executive Officer of 374Water. “We have always valued Mr. Nagar’s contributions to the Company and look forward to continued collaboration in the future. This settlement marks a new chapter, and we are excited about the possibilities ahead.”

Mr. Nagar added “I am pleased to have this matter resolved and I look forward to seeing 374Water succeed in SCWOing the world.”

Both 374Water and Mr. Nagar remain committed to a productive and positive future, focusing on their shared goals and vision for the industry.

About 374Water 

374Water Inc. (NASDAQ: SCWO) is a global cleantech company providing innovative solutions addressing wastewater treatment and waste management issues within the municipal, federal and industrial markets. 374Water’s AirSCWO technology can reduce or eliminate disposal costs, remove operational bottlenecks, reduce litigation, discharge and other risks. AirSCWO is designed to efficiently destroy and mineralize a broad spectrum of organic non-hazardous and hazardous organic wastes producing safe dischargeable water streams, safe mineral effluent, safe vent gas, and recoverable heat energy. 374Water’s AirSCWO products destruction capacity scale from 1 ton per day to over 200 tons per day. 374Water offers capital sale and lease options, as well as turn-key waste destruction services. 374Water is a leader in innovative waste treatment solutions, dedicated to creating a greener future and eradicating harmful pollutants. Learn more by visiting www.374water.com and follow us on LinkedIn. 

Investor Relations and Media Contact 
Chris Tyson
Executive Vice President 
MZ North America 
Direct: 949-491-8235 
[email protected]
www.mzgroup.us



Posted on

MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences

MARIETTA, Ga., April 10, 2025 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will participate in the following industry conferences this quarter to feature the latest scientific and clinical data supporting the use of its portfolio of Advanced Wound Care and Surgical Solutions.

“MIMEDX’s ongoing commitment to innovation and our expanding, best-in-class body of scientific and clinical evidence will be on full display at these high-profile conferences this spring,” stated Joseph H. Capper, MIMEDX Chief Executive Officer. “We are excited to share insights with leading wound care providers and key opinion leaders at the Diabetic Limb Salvage conference, as well as at SAWC Spring.”

Mr. Capper continued, “This year, we are also thrilled to be participating in Digestive Disease Week, a new industry conference for MIMEDX and one that demonstrates our continued commitment to drive awareness and adoption of our products in surgical settings, including gastrointestinal surgery.”

MedStar Georgetown University Hospital’s Diabetic Limb Salvage (DLS) Conference

April 10-12, 2025 | Washington, D.C. | Booth 103

Sponsored Lunch Symposium

Title:
Climbing the Ladder or Taking the Elevator? Rethinking Limb Salvage Strategies

Date/Time: Thursday, April 10 / 12:20 – 1:10 p.m.
Speakers: Frank Lau, MD, FACS; Megan Oltmann, DPM, D.ABFAS, FACFAS

Symposium on Advanced Wound Care (SAWC) Spring 2025

April 30-May 4, 2025 | Grapevine, TX | Booth 800

Sponsored Lunch Symposium

Title:
Change is Inevitable: Mastering the Art of Wound Healing in an Evolving Landscape

Date/Time: Thursday, May 1 / 12:00 – 1:30 p.m.
Speakers: Paul Kim, DPM, MS, FACFAS; Nicolas Mouawad, MD, MPH, MBA, DFSVS, FRCS, FACS, RPVI; Scott R. Boynton, DPM, FACFAS

Digestive Disease Week (DDW) 2025

May 3-6, 2025 | San Diego, CA  

Oral Presentation

Title:
Hospital Readmissions & Anastamotic Leaks with the use of Amniotic Tissues in Colorectal Surgery

Date/Time: Tuesday, May 6 / 4:00 p.m.
Speaker: Bidhan Das, MD

About MIMEDX

MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

About DLS

This annual conference emphasizes a multidisciplinary team approach, equipping each member of the healthcare team with the education and resources needed to heal wounds and prevent amputations. The program features a distinguished international faculty and underscores the importance of a multispecialty approach in limb salvage. Designed for healthcare practitioners across all specialties, the course promotes evidence-based practices with a focus on actionable insights, innovative techniques, and improved patient outcomes.

About SAWC

The Symposium on Advanced Wound Care meeting (SAWC), serves as a forum to connect the entire wound care team—physicians, nurses, physical therapists, researchers, scientists, podiatrists, and dietitians—with the foremost experts in wound care to improve patient outcomes through education. No other wound care conference offers the level of education, advanced state-of-the-art clinical reviews, and emerging research findings.

About Digestive Disease Week

Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 3-6, 2025. The meeting showcases more than 4,400 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.

Contact:

Matt Notarianni
Investor Relations
470-304-7291
[email protected]



Posted on

FormFactor to Announce First Quarter 2025 Financial Results on April 30th

LIVERMORE, Calif., April 10, 2025 (GLOBE NEWSWIRE) — FormFactor, Inc. (Nasdaq: FORM) will report financial results for its 2025 fiscal first quarter on Wednesday, April 30th, 2025, at 1:25 p.m. Pacific Time. The public is invited to listen to a live webcast of FormFactor’s conference call on the Investors section of the company’s web site at www.formfactor.com.

To Listen via Telephone: Preregistration is required. Please preregister by clicking here.

Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN.

A replay of the conference call will be available approximately two hours after the conclusion of the call. The replay will be available on the Investors section of our website www.formfactor.com.

About FormFactor:

FormFactor, Inc. (NASDAQ: FORM) is a leading provider of essential test and measurement technologies along the full IC life cycle – from characterization, modeling, reliability, and design de-bug to qualification and production test. Semiconductor companies rely upon FormFactor’s products and services to accelerate profitability by optimizing device performance and advancing yield knowledge. The Company serves customers through its network of facilities in Asia, Europe, and North America. For more information, visit the Company’s website at www.formfactor.com.

Investor Contact
Stan Finkelstein
Investor Relations
(925) 290-4273
[email protected]


FORM-F



Posted on

Silvercrest Asset Management Group Appoints J. Allen Gray to Board of Directors

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) — Silvercrest Asset Management Group Inc. (NASDAQ:SAMG), a leading registered investment advisory firm specializing in institutional and wealth asset management services, is pleased to announce the appointment of J. Allen Gray to its Board of Directors, effective immediately.

Mr. Gray brings extensive experience in financial services and strategic leadership to Silvercrest. As head of Silvercrest’s institutional business, Mr. Gray has played a pivotal role in the success of the firm’s institutional equity business over his tenure. The institutional asset management business has grown to approximately 30% of its discretionary assets under management under Mr. Gray’s nearly 17-year tenure. He is a Silvercrest Partner and Managing Director, and has been a member of the company’s Executive Committee since 2019.

“We are thrilled to welcome Allen Gray to our Board of Directors,” said Richard Hough, Chairman and CEO of Silvercrest Asset Management Group Inc. “Allen will provide the Board with important strategic insights with regards to our ongoing growth in the institutional asset management business as well our global initiatives. Our ambitious growth plans will greatly benefit from Allen’s careful advice and counsel. His deep industry knowledge, proven leadership, and commitment to excellence align perfectly with Silvercrest’s mission to deliver exceptional value to our clients.”

About J. Allen Gray

J. Allen Gray is a Managing Director and Head of Institutional business. Prior to Silvercrest, Mr. Gray served as a Managing Partner and a Member of the Management Committee of Osprey Partners Investment Management, LLC and as President of the Osprey Concentrated Large Cap Value Equity Fund. Prior to Osprey Partners, Mr. Gray served as a Managing Director with Radnor Capital Management, a start-up investment firm, where he was responsible for the firm’s sales, marketing and client relations activities. Mr. Gray began his career with Kidder, Peabody & Co. as a financial advisor before accepting a position with Wheat, First Securities, Inc. as Vice President for institutional equity sales as well as continuing to work as a financial advisor to families and individuals. Mr. Gray remained with Wheat, First Securities until the founding of Radnor Capital Management. Mr. Gray received his B.A. in Political Science from Randolph-Macon College.

About Silvercrest

Silvercrest was founded in April 2002 as an independent, employee-owned registered investment adviser. With offices in New York, Boston, Virginia, New Jersey, California and Wisconsin, Silvercrest provides traditional and alternative investment advisory and family office services to wealthy families and select institutional investors. As of December 31, 2024, the firm reported assets under management of $36.5 billion.

Contact: Richard R. Hough III
Chairman & CEO
212-649-0601
[email protected]



Posted on

Cognex Announces First Quarter 2025 Earnings Release and Conference Call Dates

PR Newswire


NATICK, Mass.
, April 10, 2025 /PRNewswire/ — Cognex Corporation (NASDAQ: CGNX) will release earnings for the first quarter of 2025 on Wednesday, April 30, 2025, after market close.

The Company will host a conference call on Thursday, May 1, 2025, at 8:30 a.m. Eastern Daylight Time (EDT), to discuss the results.

Access to the conference call, and a replay that will be available following the call, may be found on the Cognex Investor Relations website at https://www.cognex.com/investor. The telephone number for the live call is (877) 704-4573 or (201) 389-0911 if outside the United States.

About Cognex
Cognex Corporation invents and commercializes technologies that address some of the most critical manufacturing and distribution challenges. We are a leading global provider of machine vision products and solutions that improve efficiency and quality in high-growth-potential businesses across attractive industrial end markets. Our solutions blend physical products and software to capture and analyze visual information, allowing for the automation of manufacturing and distribution tasks for customers worldwide. Machine vision products are used to automate the manufacturing or distribution and tracking of discrete items, such as mobile phones, electric vehicle batteries and e-commerce packages, by locating, identifying, inspecting, and measuring them. Machine vision is important for applications in which human vision is inadequate to meet requirements for size, accuracy, or speed, or in instances where substantial cost savings or quality improvements are maintained.

Cognex is the world’s leader in the machine vision industry, having shipped more than 4.5 million image-based products, representing over $11 billion in cumulative revenue, since the company’s founding in 1981. Headquartered in Natick, Massachusetts, USA, Cognex has offices and distributors located throughout the Americas, Europe, and Asia. For details, visit Cognex online at www.cognex.com.

Investor Contacts:

Greer Aviv – Senior Investor Relations Consultant
Jordan Bertier – Sr. Manager, Investor Relations
Cognex Corporation
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cognex-announces-first-quarter-2025-earnings-release-and-conference-call-dates-302426033.html

SOURCE Cognex Corporation

Posted on

First Horizon Recognized as a Newsweek America’s Greatest Workplace for Women 2025

PR Newswire


MEMPHIS, Tenn.
, April 10, 2025 /PRNewswire/ — First Horizon Corporation (NYSE: FHN), with a proud legacy of growth and innovation, has been named one of America’s Greatest Places to Work for Women in 2025, an honor that highlights the bank’s commitment to expanding access for its associates.

The recognition, awarded by Newsweek and in its third year, is based on an independent large-scale survey that includes information from interviews of more than 70,000 female workers and more than 1.4 million company reviews.

“At First Horizon, our people are our greatest asset, and this recognition reflects our ongoing commitment to fostering an environment where we live our values and where our associates feel supported and inspired to grow in their career,” said Tanya Hart, First Horizon Chief Human Resources Officer. “From our leadership programming to an ongoing commitment to excellence, we are dedicated to creating a culture for associates that attracts and retains top talent.”

First Horizon extends its congratulations to all of the honorees included in Newsweek’s America’s Greatest Workplaces for Women 2025.

About First Horizon 
First Horizon Corp. (NYSE: FHN), with $82.2 billion in assets as of December 31, 2024, is a leading regional financial services company, dedicated to helping our clients, communities and associates unlock their full potential with capital and counsel. Headquartered in Memphis, TN, the banking subsidiary First Horizon Bank operates in 12 states across the southern U.S. The Company and its subsidiaries offer commercial, private banking, consumer, small business, wealth and trust management, retail brokerage, capital markets, fixed income, and mortgage banking services. First Horizon has been recognized as one of the nation’s best employers by Fortune and Forbes magazines and a Top 10 Most Reputable U.S. Bank. More information is available at www.firsthorizon.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/first-horizon-recognized-as-a-newsweek-americas-greatest-workplace-for-women-2025-302426002.html

SOURCE First Horizon Bank